Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1393&sort=keywords
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=keywords", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=keywords", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1394&sort=keywords", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=keywords" }, "data": [ { "type": "Grant", "id": "8616", "attributes": { "award_id": "75N92021D00008-0-759202100005-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) CLINICAL EVALUATION SERVICES", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-08-06", "end_date": "2021-11-26", "award_amount": 2685235, "principal_investigator": { "id": 23973, "first_name": "MARK", "last_name": "MARINO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1670, "ror": "https://ror.org/00mgk5c15", "name": "VentureWell", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has an open solicitation for proposals to provide up to $500 million across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.", "keywords": [ "American", "COVID-19", "COVID-19 detection", "COVID-19 diagnostic", "COVID-19 testing", "Centers for Disease Control and Prevention (U.S.)", "Clinical", "Contracts", "Department of Defense", "Development", "Device Designs", "Diagnostic tests", "Ensure", "Exhalation", "Funding", "Goals", "Home", "Improve Access", "Laboratories", "Life Cycle Stages", "Modification", "National Institute of Biomedical Imaging and Bioengineering", "Patients", "Performance", "Point of Care Technology", "Privatization", "Program Development", "RADx", "Readiness", "Research", "Saliva", "Sampling", "Seasons", "Sensitivity and Specificity", "Services", "Speed", "Structure", "Technology", "Test Result", "Testing", "Time", "TimeLine", "United States National Institutes of Health", "Validation", "Virus", "base", "commercialization", "cost", "design", "detection limit", "flu", "handheld mobile device", "home test", "improved", "innovation", "meetings", "novel", "point of care", "product development", "programs", "research clinical testing", "scale up", "technology development", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "10929", "attributes": { "award_id": "5R41AI167078-02", "title": "A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6606, "first_name": "Lanling", "last_name": "Zou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-01-01", "end_date": "2023-12-31", "award_amount": 293112, "principal_investigator": { "id": 22740, "first_name": "Christian", "last_name": "Harding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1530, "ror": "", "name": "VAXNEWMO, LLC", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1530, "ror": "", "name": "VAXNEWMO, LLC", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (hvKp). cKp commonly acts as an opportunistic pathogen causing disease in hospitalized or immunocompromised individuals. In fact, cKp is annually responsible for 5% of all healthcare-associated infections and is the leading cause of nosocomial pneumonia in the US. Furthermore, cKp isolates are often carbapenem-resistant (CR), limiting treatment options. In the US, K. pneumoniae multilocus sequence type 258 (ST258) strains account for ~70% of all carbapenem- resistant K. pneumoniae infections. Conversely, hvKp usually cause community-acquired infections in healthy hosts that frequently manifest as community-acquired pneumonia. Like ST258 infections, hvKp infections have high mortality rates approaching 40-60%. Currently, there are no licensed vaccines available to prevent K. pneumoniae infections and none in clinical trials. Nevertheless, preliminary data demonstrate both cKp and hvKp infections can be prevented by vaccines that target their capsular polysaccharide (CPS). Conjugate vaccines consist of a CPS covalently attached to an immunogenic carrier protein. While the clinical benefits of conjugate vaccines are well documented, the development of new conjugate vaccines targeting K. pneumoniae is lagging, likely due to the high technological barriers to entry and high costs associated with conjugate vaccine production. In addition, most conjugate vaccines are multivalent, further increasing manufacturing complexities. In order to simplify conjugate vaccine production, we have developed an in vivo conjugation platform termed bioconjugation. Bioconjugation allows for the simultaneous production of the CPS, the carrier protein and their subsequent covalent linkage all within E. coli. Key to our bioconjugation platform is our patented conjugating enzyme, PglS, which attaches virtually any polysaccharide to a unique amino acid sequence fused to the carrier protein. Furthermore, bioconjugation is modular, allowing for rapid production of multiple, different CPS-protein conjugates. Using our bioconjugation platform, we are developing a multivalent CPS-based bioconjugate vaccine to prevent the majority of K. pneumoniae infections. In this Phase I STTR program, four serotypes were initially selected (K1, K2, KL106, KL107) as these serotypes are associated with >80% of all hvKp (K1 and K2) isolates worldwide and >70% of ST258 (KL106 and KL107) isolates in the US. In Aim 1, we will produce a tetravalent (K1, K2, KL106, KL107) bioconjugate vaccine on a modified carrier protein glycosylated at an internal site, which is expected to improve conjugate characteristics such as stability and immunogenicity. In Aim 2, we will test the tetravalent bioconjugate vaccine in a dose-escalation study to determine an optimal dose. Finally, in Aim 3, we will challenge groups of placebo- or bioconjugate-vaccinated mice with either a ST258 strain (KL106 and KL107) or a hvKp strain (K1 and K2) and assess survival as a surrogate for vaccine efficacy.", "keywords": [ "Americas", "Amino Acid Sequence", "Antibiotics", "Antibody Response", "Bacterial Pneumonia", "COVID-19 patient", "COVID-19 pneumonia", "Carbapenems", "Carrier Proteins", "Cessation of life", "Characteristics", "Chemistry", "Clinical", "Clinical Trials", "Colony-forming units", "Communities", "Community-Acquired Infections", "Conjugate Vaccines", "Data", "Development", "Disease", "Dose", "Encapsulated", "Enzymes", "Escherichia coli", "Europe", "Formulation", "Genomics", "Goals", "Hospitalization", "Human", "Immunization", "Immunocompromised Host", "Immunoglobulin G", "Individual", "Infection", "Klebsiella pneumoniae", "Legal patent", "Licensing", "Modeling", "Multi-Drug Resistance", "Mus", "Names", "Nosocomial pneumonia", "Phase", "Pneumococcal conjugate vaccine", "Polysaccharides", "Prevnar", "Production", "Protein Glycosylation", "Proteins", "Resistance", "Serotyping", "Site", "Small Business Technology Transfer Research", "Southern Europe", "Syndrome", "Technology", "Testing", "Vaccinated", "Vaccination", "Vaccine Production", "Vaccines", "Virulent", "active control", "base", "capsule", "carbapenem resistance", "clinically relevant", "commercialization", "community acquired pneumonia", "cost", "glycosylation", "healthcare-associated infections", "human pathogen", "immunogenic", "immunogenicity", "improved", "in vivo", "mortality", "mouse model", "opportunistic pathogen", "pathogenic bacteria", "placebo group", "prevent", "programs", "prototype", "research and development", "resistant Klebsiella pneumoniae", "vaccine access", "vaccine development", "vaccine efficacy", "virtual" ], "approved": true } }, { "type": "Grant", "id": "6907", "attributes": { "award_id": "1R41AI167078-01", "title": "A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6606, "first_name": "Lanling", "last_name": "Zou", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-01-01", "end_date": "2023-12-31", "award_amount": 300000, "principal_investigator": { "id": 22740, "first_name": "Christian", "last_name": "Harding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1530, "ror": "", "name": "VAXNEWMO, LLC", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1530, "ror": "", "name": "VAXNEWMO, LLC", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (hvKp). cKp commonly acts as an opportunistic pathogen causing disease in hospitalized or immunocompromised individuals. In fact, cKp is annually responsible for 5% of all healthcare-associated infections and is the leading cause of nosocomial pneumonia in the US. Furthermore, cKp isolates are often carbapenem-resistant (CR), limiting treatment options. In the US, K. pneumoniae multilocus sequence type 258 (ST258) strains account for ~70% of all carbapenem- resistant K. pneumoniae infections. Conversely, hvKp usually cause community-acquired infections in healthy hosts that frequently manifest as community-acquired pneumonia. Like ST258 infections, hvKp infections have high mortality rates approaching 40-60%. Currently, there are no licensed vaccines available to prevent K. pneumoniae infections and none in clinical trials. Nevertheless, preliminary data demonstrate both cKp and hvKp infections can be prevented by vaccines that target their capsular polysaccharide (CPS). Conjugate vaccines consist of a CPS covalently attached to an immunogenic carrier protein. While the clinical benefits of conjugate vaccines are well documented, the development of new conjugate vaccines targeting K. pneumoniae is lagging, likely due to the high technological barriers to entry and high costs associated with conjugate vaccine production. In addition, most conjugate vaccines are multivalent, further increasing manufacturing complexities. In order to simplify conjugate vaccine production, we have developed an in vivo conjugation platform termed bioconjugation. Bioconjugation allows for the simultaneous production of the CPS, the carrier protein and their subsequent covalent linkage all within E. coli. Key to our bioconjugation platform is our patented conjugating enzyme, PglS, which attaches virtually any polysaccharide to a unique amino acid sequence fused to the carrier protein. Furthermore, bioconjugation is modular, allowing for rapid production of multiple, different CPS-protein conjugates. Using our bioconjugation platform, we are developing a multivalent CPS-based bioconjugate vaccine to prevent the majority of K. pneumoniae infections. In this Phase I STTR program, four serotypes were initially selected (K1, K2, KL106, KL107) as these serotypes are associated with >80% of all hvKp (K1 and K2) isolates worldwide and >70% of ST258 (KL106 and KL107) isolates in the US. In Aim 1, we will produce a tetravalent (K1, K2, KL106, KL107) bioconjugate vaccine on a modified carrier protein glycosylated at an internal site, which is expected to improve conjugate characteristics such as stability and immunogenicity. In Aim 2, we will test the tetravalent bioconjugate vaccine in a dose-escalation study to determine an optimal dose. Finally, in Aim 3, we will challenge groups of placebo- or bioconjugate-vaccinated mice with either a ST258 strain (KL106 and KL107) or a hvKp strain (K1 and K2) and assess survival as a surrogate for vaccine efficacy.", "keywords": [ "Americas", "Amino Acid Sequence", "Antibiotics", "Antibody Response", "Bacterial Pneumonia", "COVID-19 patient", "COVID-19 pneumonia", "Carbapenems", "Carrier Proteins", "Cessation of life", "Characteristics", "Chemistry", "Clinical", "Clinical Trials", "Colony-forming units", "Communities", "Community-Acquired Infections", "Conjugate Vaccines", "Data", "Development", "Disease", "Dose", "Encapsulated", "Enzymes", "Escherichia coli", "Europe", "Formulation", "Genomics", "Goals", "Human", "Immunization", "Immunocompromised Host", "Immunoglobulin G", "Individual", "Infection", "Klebsiella pneumoniae", "Legal patent", "Modeling", "Multi-Drug Resistance", "Mus", "Names", "Nosocomial pneumonia", "Phase", "Pneumococcal conjugate vaccine", "Polysaccharides", "Prevnar", "Production", "Proteins", "Resistance", "Serotyping", "Site", "Small Business Technology Transfer Research", "Southern Europe", "Syndrome", "Technology", "Testing", "Vaccinated", "Vaccination", "Vaccine Production", "Vaccines", "Virulent", "base", "capsule", "carbapenem resistance", "clinically relevant", "commercialization", "community acquired pneumonia", "cost", "glycosylation", "healthcare-associated infections", "human pathogen", "immunogenic", "immunogenicity", "improved", "in vivo", "mortality", "mouse model", "opportunistic pathogen", "pathogenic bacteria", "placebo group", "prevent", "programs", "prototype", "research and development", "resistant Klebsiella pneumoniae", "vaccine access", "vaccine development", "vaccine efficacy", "virtual" ], "approved": true } }, { "type": "Grant", "id": "8597", "attributes": { "award_id": "1R13HL158207-01", "title": "Cardiovascular Bioengineering 2021 Symposium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24372, "first_name": "Martha", "last_name": "Lundberg", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-08-15", "end_date": "2022-07-31", "award_amount": 10000, "principal_investigator": { "id": 24373, "first_name": "Timothy J.", "last_name": "Kamp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "This is a new application for the Cardiovascular Bioengineering 2021 (CVBE 2021) Symposium to be held on the campus of the University of Göttingen, Germany. This will be the 6th Anniversary of the Symposium. The uniqueness of the proposed CVBE symposium lies in its combination of top researchers in cardiovascular bioengineering with underrepresented trainees in the field. Trainees are graduate students and post-doctoral fellows in the cardiovascular sciences and biomedical engineering. The symposium will provide a forum for trainees and junior investigators to present their work in the areas of gene editing, induced pluripotent stem cells, and cardiac stem cells in the context of heart failure as well general topics in cardiovascular bioengineering. This conference grew out of initiatives from the NHLBI progenitor cell biology consortium (PCBC) and brought together initially PCBC cardiovascular researchers and their trainees as well as invited speakers. In 2016, as the PCBC was replaced by NHLBI progenitor cell translation consortium (PCTC), the meeting grew to a public symposium to broadly engage both PCBC investigators as well as others in in cardiovascular bioengineering. Proceedings and position papers have emerged from the meeting over the years,1-5 and it is now recognized as a unique public and recurring scientific symposium of stem cell and cardiovascular bioengineering. The conference in the past 4 years has added translational topics as well as the “bread and butter” of this meeting, which is the convergences of stem cell biology bioengineering, molecular cardiovascular research, and fabrication of functional myocardium. The conference topics started with tissue engineering, iPS cells, cardiac development, and in the past 2 years has grown to include exosome, microRNAs, mitochondria, cardiac gene and cardiac cell therapy. The attendance of this conference has climbed and, in 2019, the symposium was held at the University of Sydney, Australia. There were nearly 200 attendees from Australia, New Zealand, China, Japan, Europe, and America. In past years, the conference was held in March. The conference was planned for 2020 at the University of Göttingen, but the meeting was cancelled due to COVID-19. Fortunately, we are able to reschedule the meeting for 2021. The planned agenda represents an ambitious, fast-paced meeting with multiple sessions over 2 days including the Keynote lecture. Young cardiovascular scientists will be highlighted through invited talks at each session. Organizers of this meeting are Drs. Wolfram-Hubertus Zimmermann (Göttingen), Jianyi (Jay) Zhang (UAB), Timothy Kamp (UW-Madison), Malte Tiburcy (Göttingen), Laura Zelarayan (Göttingen), Susanne Lutz (Göttingen), Norman Liaw (Göttingen), Patapia Zafeiriou (Göttingen), and Rabea Hinkel (Göttingen). The proposal request of $10,000 constitutes approximately 20% of the total meeting budget, and as we have done over the last several years, support from this application will be used towards the cost of trainee travel, minority travel awards, new investigator travel, and support for videotaping all sessions that will be assessable to the public (Click here to view 2019 CVBE Symposium videos).", "keywords": [ "Americas", "Anniversary", "Area", "Australia", "Award", "Biomedical Engineering", "Budgets", "COVID-19", "Cardiac", "Cardiac development", "Cardiovascular system", "Cell Therapy", "Cells", "Cellular biology", "China", "Collaborations", "Europe", "Fostering", "Genes", "Germany", "Goals", "Grant", "Heart Diseases", "Heart failure", "Individual", "Innovative Therapy", "International", "Japan", "Learning", "Life", "MicroRNAs", "Minority", "Mitochondria", "Molecular", "Myocardium", "National Heart Lung and Blood Institute", "New Zealand", "Paper", "Pluripotent Stem Cells", "Positioning Attribute", "Postdoctoral Fellow", "Request for Proposals", "Research", "Research Personnel", "Schedule", "Science", "Scientist", "Tissue Engineering", "Translations", "Travel", "Tungsten", "Underrepresented Minority", "Universities", "Videotape", "Work", "career", "cost", "design", "exosome", "experience", "graduate student", "induced pluripotent stem cell", "lectures", "meetings", "next generation", "outreach", "programs", "recruit", "stem cell biology", "stem cells", "symposium" ], "approved": true } }, { "type": "Grant", "id": "9197", "attributes": { "award_id": "75N92020C00017-P00001-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) PROGRAM: TECH PROJECT NO 2375 - MASSIVELY PARALLEL CENTRALIZED AND DECENTRALIZED ULTRAFAST COVID-19INFECTIOUS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-30", "end_date": "2021-09-29", "award_amount": 7200049, "principal_investigator": { "id": 24949, "first_name": "DAVID", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "Conscious", "Decentralization", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Provider", "RADx", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "coronavirus disease", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "programs", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "6681", "attributes": { "award_id": "75N92021C00018-P00002-9999-1", "title": "RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2022-06-30", "award_amount": 12970000, "principal_investigator": { "id": 22379, "first_name": "DAVE", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "COVID-19 testing", "Conscious", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Persons", "Provider", "RADx Tech", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "base", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "8432", "attributes": { "award_id": "75N92021C00018-0-9999-1", "title": "RADX TECH 2375 - POINT OF NEED, SALIVA-BASED, COVID-19 TESTING PLATFORMS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-07-01", "end_date": "2022-06-30", "award_amount": 3700000, "principal_investigator": { "id": 22342, "first_name": "DAVE", "last_name": "BEEBE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The key conceptual insight underpinning this proposal is that detecting individuals who are most likely to transmit SARS-CoV-2 is essential to mitigating the pandemic and reopening America. Our approach consciously contrasts with most existing nucleic acid testing platforms, which begin from the premise that maximizing detection sensitivity is the goal. We argue that striving for maximum sensitivity is at odds with the current needs for broad population based testing and that in a public health emergency, nucleic acid testing should be designed to maximize the number of people who can be tested for high viral loads consistent with shedding of live virus, in the greatest number of settings, at the lowest possible cost. To achieve this we couple a proven, ultrafast nucleic acid extraction method with rapid detection of amplified nucleic acids in an assay that can be both massively scaled in centralized reference labs and also used by point-of-care testing providers. The key enabling technology is a new, but proven, nucleic acid extraction method that reliably, quickly, and easily extracts, purifies, and concentrates viral RNA from a variety of sample types including nasal swabs and saliva in a highly parallel format. RNA prepared using this extraction method can be reliably amplified and detected using a simple colorimetric assay following isothermal amplification. These two technologies combined provide a testing platform that can enable millions of tests a week, at low cost, in both centralized laboratories and at point-of-care using technicians with no specialized training to support test/isolate/trace.", "keywords": [ "Americas", "Biological Assay", "COVID-19 testing", "Conscious", "Goals", "Individual", "Laboratories", "Methods", "Nucleic Acid Amplification Tests", "Nucleic Acids", "Provider", "RADx Tech", "RNA", "SARS-CoV-2 transmission", "Saliva", "Sampling", "Technology", "Testing", "Training", "Viral Load result", "Virus", "amplification detection", "base", "cost", "design", "detection sensitivity", "insight", "isothermal amplification", "nasal swab", "pandemic disease", "point of care", "point of care testing", "population based", "public health emergency", "rapid detection", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "6348", "attributes": { "award_id": "3U45ES006185-30S1", "title": "Hazardous Materials Worker Health and Safety Training", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 21400, "first_name": "Sharon", "last_name": "Beard", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "1992-09-21", "end_date": "2022-05-31", "award_amount": 300000, "principal_investigator": { "id": 21401, "first_name": "CHRISTINA TRAHAN", "last_name": "CAIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1452, "ror": "", "name": "CENTER FOR CONSTRUCTION RES AND TRAINING", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1452, "ror": "", "name": "CENTER FOR CONSTRUCTION RES AND TRAINING", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Overall Project Summary/Abstract As a 501 (c)(3) not-for-profit institution created for the sole purpose of improving working conditions in the U.S. construction industry, CPWR’s mission aligns with the goals of the NIEHS Worker Training Program (WTP). CPWR’s purpose as an organization, as stated in its Articles of Incorporation are; “to encourage the elimination or reduction of conditions constituting hazards to the health or safety of workers, and to promote the maintenance and improvement of safe and healthy working conditions for workers.” Beyond these broad, long-term objectives of CPWR as an organization, the specific aims of this proposed training program are: 1) to train 9,535 students in 620 courses over a five year period, and to continue instructor development through annual Train-the-Trainer programs and Instructor Enhancements (HWWTP); 2) to train 300 minority workers over a five year period in three cities (New Orleans, LA; St. Paul, MN; and East Palo Alto, CA) and place at least 80% in construction union apprenticeship training programs for jobs in the construction and environmental remediation industries (EWCTP); 3) to directly train 1,815 additional Outreach Instructors in the disaster program over a five year period, while partially supporting more than 4,800 additional Outreach Instructors, and to continue to work with NIEHS, other grantees, and OSHA in moving the training forward as part of our collective efforts to increase preparedness in the U.S. construction industry to respond to large scale natural and man-made disasters (HDPTP); and 4) continue rigorous evaluation over the five year period to continuously assess training effectiveness of all three programs. To achieve these aims, CPWR submits this application in coordination and cooperation with a training consortium of 11 international/national building trades unions representing workers engaged in hazardous waste work at designated 1910.120 sites around the country and in other environmentally hazardous work assignments. Our proposed program is therefore national in scope, with our building trades union training consortium representing more than 3 million construction workers geographically dispersed throughout every state in the nation. CPWR’s building trades union training consortium is diverse, with each of our 11 partnering unions representing workers that apply different skills necessary on environment remediation sites. Typical of the cyclical, transient nature of the industry and its workforce, our target population of workers move on and off environmental remediation sites, often moving from one employer to another. The HWWTP proposal in this application describes in detail the types of jobs workers represented by each of our 11 consortium partners perform on designated 1910.120 sites. Whether they work on these sites for years, months, weeks, or just a few days, with the support of this proposed program CPWR and its 11 consortium partners aim to assure these workers are adequately trained to protect themselves, their co-workers, and their environment.", "keywords": [ "Americas", "Canada", "Cities", "Communities", "Country", "Development", "Disasters", "Effectiveness", "Environment", "Evaluation", "Family", "Geography", "Goals", "Hazardous Substances", "Hazardous Waste", "Health", "Industry", "Injury", "Institution", "International", "Iron", "Letters", "Maintenance", "Metals", "Minority", "Mission", "National Institute of Environmental Health Sciences", "Nature", "Occupations", "Periodicity", "Plumbing", "Population", "Public Health", "Readiness", "Safety", "Ships", "Site", "Structure", "Students", "Target Populations", "Trade Unions", "Trainers Training", "Training", "Training Programs", "United States", "Work", "apprenticeship", "hazard", "improved", "instructor", "man", "outreach", "programs", "remediation", "skills" ], "approved": true } }, { "type": "Grant", "id": "5789", "attributes": { "award_id": "3R01AI148416-02S1", "title": "Cooption of the DNA Damage Response For Epigenetic Regulation of Inflammation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19905, "first_name": "QIAN", "last_name": "Liu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-12-01", "end_date": "2024-11-30", "award_amount": 329155, "principal_investigator": { "id": 19906, "first_name": "Steven Zvi", "last_name": "Josefowicz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Complex organisms are able to rapidly induce select genes among thousands in response to diverse environmental cues. This occurs in the context of large genomes condensed with histone proteins into chromatin. The macrophage response to pathogen sensing, for example, rapidly engages highly conserved signaling pathways and transcription factors (TFs) for coordination of inflammatory gene induction. Enriched integration of histone H3.3, the ancestral histone H3 variant, is a feature of inflammatory genes and, in general, dynamically regulated chromatin and transcription. The amino-terminal H3.3 `tail' differs from the other H3 proteins by a single amino acid, a serine at position 31. However, little is known of how (or which) features of H3.3, conserved from yeast to human, might enable rapid and high-level transcription. We have recently discovered a potent function for H3.3-specific histone phosphorylation (H3.3S31ph) in inflammatory gene transcription and surprising evidence that non-canonical activity of the DNA-damage response (DDR) pathway mediates this histone phosphorylation. Thus, we hypothesize that the DDR pathway is coopted for epigenetic regulation of inflammatory genes. In Aim 1 we will identify the factors and sequence of events that link DDR factors and H3.3S31ph to rapid inflammatory gene transcription and reveal the function of cross-talk between DDR and chromatin (H3.3S31ph) by employing novel histone mutant mouse models. Specifically, our experiments will enable us to distinguish between several candidate “paths” to H3.3S31ph and amplification of transcription, including Topoisomerase dependency, and DNA break-dependent and -independent pathways. In Aim 2 we will identify how DDR-mediated H3.3S31ph uniquely regulates Pol II dynamics at select inflammatory genes to amplify their transcription. More generally, these studies will identify dedicated mechanisms that enable inflammatory gene induction with important implications for understanding inflammation and for informing more selective therapeutic strategies for diverse inflammatory diseases.", "keywords": [ "Amino Acids", "Amplifiers", "Autoimmunity", "Biochemical", "Biology", "CHEK1 gene", "Cells", "Chromatin", "Complex", "Cues", "DNA", "DNA Damage", "DNA Polymerase II", "DNA Topoisomerases", "Dependence", "Disease", "Environmental Risk Factor", "Epigenetic Process", "Event", "Gene Expression", "Genes", "Genetic Transcription", "Genome", "Goals", "Histone Code", "Histone H3", "Histones", "Human", "Immune", "Immunity", "Inflammation", "Inflammatory", "Inflammatory Response", "Knowledge", "Link", "Mediating", "Memory", "Molecular", "Mutation", "Oncogenic", "Organism", "Paper", "Pathway interactions", "Phosphorylation", "Polymerase", "Positioning Attribute", "Post-Translational Protein Processing", "Proteins", "Role", "Serine", "Signal Pathway", "Signal Transduction", "Site", "Specificity", "Speed", "Tail", "Therapeutic", "Time", "Tissues", "Topoisomerase", "Training", "Transcription Coactivator", "Variant", "Yeasts", "cell type", "crosslink", "epigenetic regulation", "epigenomics", "experimental study", "extracellular", "gene induction", "in vivo", "insight", "macrophage", "meter", "mutant mouse model", "novel", "pathogen", "protein H(3)", "recruit", "response", "therapeutic target", "transcription factor", "tumor", "upstream kinase" ], "approved": true } }, { "type": "Grant", "id": "5055", "attributes": { "award_id": "3R01AI148416-03S1", "title": "Cooption of the DNA Damage Response For Epigenetic Regulation of Inflammation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18080, "first_name": "QIAN", "last_name": "Liu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2019-12-01", "end_date": "2024-11-30", "award_amount": 17164, "principal_investigator": { "id": 18081, "first_name": "Steven Zvi", "last_name": "Josefowicz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Complex organisms are able to rapidly induce select genes among thousands in response to diverse environmental cues. This occurs in the context of large genomes condensed with histone proteins into chromatin. The macrophage response to pathogen sensing, for example, rapidly engages highly conserved signaling pathways and transcription factors (TFs) for coordination of inflammatory gene induction. Enriched integration of histone H3.3, the ancestral histone H3 variant, is a feature of inflammatory genes and, in general, dynamically regulated chromatin and transcription. The amino-terminal H3.3 `tail' differs from the other H3 proteins by a single amino acid, a serine at position 31. However, little is known of how (or which) features of H3.3, conserved from yeast to human, might enable rapid and high-level transcription. We have recently discovered a potent function for H3.3-specific histone phosphorylation (H3.3S31ph) in inflammatory gene transcription and surprising evidence that non-canonical activity of the DNA-damage response (DDR) pathway mediates this histone phosphorylation. Thus, we hypothesize that the DDR pathway is coopted for epigenetic regulation of inflammatory genes. In Aim 1 we will identify the factors and sequence of events that link DDR factors and H3.3S31ph to rapid inflammatory gene transcription and reveal the function of cross-talk between DDR and chromatin (H3.3S31ph) by employing novel histone mutant mouse models. Specifically, our experiments will enable us to distinguish between several candidate “paths” to H3.3S31ph and amplification of transcription, including Topoisomerase dependency, and DNA break-dependent and -independent pathways. In Aim 2 we will identify how DDR-mediated H3.3S31ph uniquely regulates Pol II dynamics at select inflammatory genes to amplify their transcription. More generally, these studies will identify dedicated mechanisms that enable inflammatory gene induction with important implications for understanding inflammation and for informing more selective therapeutic strategies for diverse inflammatory diseases.", "keywords": [ "Amino Acids", "Amplifiers", "Autoimmunity", "Biochemical", "Biology", "CHEK1 gene", "Cells", "Chromatin", "Complex", "Cues", "DNA", "DNA Damage", "DNA Polymerase II", "DNA Topoisomerases", "Dependence", "Disease", "Environmental Risk Factor", "Epigenetic Process", "Event", "Gene Expression", "Genes", "Genetic Transcription", "Genome", "Goals", "Histone Code", "Histone H3", "Histones", "Human", "Immune", "Immunity", "Inflammation", "Inflammatory", "Inflammatory Response", "Knowledge", "Link", "Mediating", "Memory", "Molecular", "Mutation", "Oncogenic", "Organism", "Paper", "Pathway interactions", "Phosphorylation", "Polymerase", "Positioning Attribute", "Post-Translational Protein Processing", "Proteins", "Role", "Serine", "Signal Pathway", "Signal Transduction", "Site", "Specificity", "Speed", "Tail", "Therapeutic", "Time", "Tissues", "Topoisomerase", "Training", "Transcription Coactivator", "Variant", "Yeasts", "cell type", "crosslink", "epigenetic regulation", "epigenomics", "experimental study", "extracellular", "gene induction", "in vivo", "insight", "macrophage", "meter", "mutant mouse model", "novel", "pathogen", "protein H(3)", "recruit", "response", "therapeutic target", "transcription factor", "tumor", "upstream kinase" ], "approved": true } } ], "meta": { "pagination": { "page": 1393, "pages": 1424, "count": 14236 } } }